Citigroup’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.02M | Hold |
15,000
| – | – | ﹤0.01% | 3101 |
|
|
2025
Q4 | $1.14M | Buy |
+15,000
| New | +$1.09M | ﹤0.01% | 3054 |
|
|
2025
Q3 | – | Sell |
-30,000
| Closed | -$1.47M | – | 6269 |
|
|
2025
Q2 | $1.47M | Hold |
30,000
| – | – | ﹤0.01% | 2917 |
|
|
2025
Q1 | $1.53M | Buy |
+30,000
| New | +$1.5M | ﹤0.01% | 2939 |
|
|
2024
Q4 | – | Sell |
-13,500
| Closed | -$501K | – | 5921 |
|
|
2024
Q3 | $501K | Buy |
+13,500
| New | +$452K | ﹤0.01% | 3724 |
|
|
2024
Q2 | – | Sell |
-24,800
| Closed | -$721K | – | 5736 |
|
|
2024
Q1 | $721K | Buy |
+24,800
| New | +$695K | ﹤0.01% | 3285 |
|
|
2023
Q3 | – | Sell |
-60,000
| Closed | -$2.44M | – | 5766 |
|
|
2023
Q2 | $2.44M | Buy |
60,000
+30,200
| +101% | +$1.48M | ﹤0.01% | 2022 |
|
|
2023
Q1 | $1.44M | Sell |
29,800
-21,400
| -42% | -$978K | ﹤0.01% | 2250 |
|
|
2022
Q4 | $1.95M | Buy |
51,200
+26,200
| +105% | +$1.09M | ﹤0.01% | 2059 |
|
|
2022
Q3 | $1.25M | Sell |
25,000
-5,000
| -17% | -$245K | ﹤0.01% | 2536 |
|
|
2022
Q2 | $1.2M | Buy |
+30,000
| New | +$1.05M | ﹤0.01% | 2506 |
|
|
2020
Q4 | – | Sell |
-4,600
| Closed | -$215K | – | 7573 |
|
|
2020
Q3 | $215K | Sell |
4,600
-2,900
| -39% | -$143K | ﹤0.01% | 4564 |
|
|
2020
Q2 | $381K | Buy |
7,500
+3,200
| +74% | +$157K | ﹤0.01% | 4507 |
|
|
2020
Q1 | $192K | Sell |
4,300
-28,100
| -87% | -$1.41M | ﹤0.01% | 4770 |
|
|
2019
Q4 | $1.56M | Buy |
32,400
+4,000
| +14% | +$170K | ﹤0.01% | 3272 |
|
|
2019
Q3 | $960K | Buy |
28,400
+18,100
| +176% | +$788K | ﹤0.01% | 3696 |
|
|
2019
Q2 | $464K | Buy |
10,300
+6,700
| +186% | +$265K | ﹤0.01% | 4500 |
|
|
2019
Q1 | $136K | Sell |
3,600
-2,900
| -45% | -$97.4K | ﹤0.01% | 5463 |
|
|
2018
Q4 | $223K | Buy |
6,500
+300
| +5% | +$10.8K | ﹤0.01% | 4909 |
|
|
2018
Q3 | $291K | Sell |
6,200
-6,300
| -50% | -$261K | ﹤0.01% | 4874 |
|
|
2018
Q2 | $422K | Buy |
12,500
+5,600
| +81% | +$175K | ﹤0.01% | 4296 |
|
|
2018
Q1 | $187K | Sell |
6,900
-18,500
| -73% | -$469K | ﹤0.01% | 5035 |
|
|
2017
Q4 | $424K | Buy |
25,400
+8,300
| +49% | +$140K | ﹤0.01% | 4276 |
|
|
2017
Q3 | $342K | Buy |
17,100
+11,700
| +217% | +$229K | ﹤0.01% | 4503 |
|
|
2017
Q2 | $99K | Buy |
5,400
+400
| +8% | +$5.39K | ﹤0.01% | 5345 |
|
|
2017
Q1 | $49K | Sell |
5,000
-10,400
| -68% | -$126K | ﹤0.01% | 5711 |
|
|
2016
Q4 | $168K | Sell |
15,400
-3,000
| -16% | -$31.5K | ﹤0.01% | 5429 |
|
|
2016
Q3 | $258K | Buy |
18,400
+16,000
| +667% | +$130K | ﹤0.01% | 4462 |
|
|
2016
Q2 | $17K | Buy |
+2,400
| New | +$17.6K | ﹤0.01% | 6249 |
|
|
2015
Q3 | – | Sell |
-1,100
| Closed | -$53K | – | 7637 |
|
|
2015
Q2 | $53K | Buy |
+1,100
| New | +$64.2K | ﹤0.01% | 5491 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Citigroup's PTCT Position: Q1 2026 in Review
Citigroup reduced its PTC Therapeutics (PTCT) stake by 32% in Q1 2026, selling an estimated $745K and leaving 22,146 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2850.
Citigroup first reported a position in PTCT in Q3 2013 and has held it in 51 quarters since. The position peaked at $15.6M in Q1 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Citigroup held 22,146 shares of PTC Therapeutics worth $1.51M as of Q1 2026.
- Citigroup sold 10,515 PTC Therapeutics shares in Q1 2026, an estimated $745K.
- PTC Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2850 holding.
- Citigroup first reported a position in PTC Therapeutics in Q3 2013 and has held it in 51 quarters since.
- Citigroup's PTC Therapeutics position peaked at $15.6M in Q1 2025.
- 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.